CRL

155.46

1.83% 2.80

Dopo l'orario di chiusura: 155.46

Charles River Laboratories International Inc (CRL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$152.66

Aprire:

$155.62

Volume 24 ore:

987.47K

Relative Volume:

1.08

Capitalizzazione di mercato:

$7.65B

Reddito:

$4.02B

Utile/perdita netta:

$-79.62M

Rapporto P/E:

-99.97

EPS:

-1.5551

Flusso di cassa netto:

$543.67M

1 W Prestazione:

-10.89%

1M Prestazione:

-3.65%

6M Prestazione:

+1.68%

1 anno Prestazione:

-6.87%

Intervallo 1D:

$153.04

$158.76

Intervallo di 1 settimana:

$151.89

$178.05

Portata 52W:

$91.86

$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Nome

Charles River Laboratories International Inc

Settore

Healthcare (1116)

Industria

Diagnostics & Research (52)

Telefono

781-222-6000

Indirizzo

251 BALLARDVALE ST, WILMINGTON, MA

Dipendente

19,700

Cinguettio

@criverlabs

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRL Charles River Laboratories International Inc	155.46	7.65B	4.02B	-79.62M	543.67M	-1.5551
TMO Thermo Fisher Scientific Inc	464.37	172.51B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	187.32	132.46B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	573.82	45.69B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	111.51	31.51B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	286.57	28.11B	3.17B	642.63M	516.49M	10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-15	Aggiornamento	BofA Securities	Neutral → Buy
2025-11-17	Aggiornamento	Argus	Hold → Buy
2025-11-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2025-10-06	Aggiornamento	William Blair	Mkt Perform → Outperform
2025-10-02	Aggiornamento	Barclays	Equal Weight → Overweight
2025-09-09	Aggiornamento	Jefferies	Hold → Buy
2025-07-09	Aggiornamento	Citigroup	Neutral → Buy
2025-05-23	Aggiornamento	Redburn Atlantic	Neutral → Buy
2025-05-14	Aggiornamento	TD Cowen	Hold → Buy
2025-05-08	Aggiornamento	Evercore ISI	In-line → Outperform
2025-03-21	Downgrade	Goldman	Buy → Neutral
2025-03-04	Aggiornamento	Citigroup	Sell → Neutral
2025-03-03	Aggiornamento	Redburn Atlantic	Sell → Neutral
2025-01-22	Downgrade	William Blair	Outperform → Mkt Perform
2025-01-17	Downgrade	UBS	Buy → Neutral
2024-11-18	Downgrade	CLSA	Hold → Underperform
2024-11-07	Aggiornamento	CLSA	Underperform → Hold
2024-10-23	Iniziato	CLSA	Underperform
2024-10-14	Iniziato	Redburn Atlantic	Sell
2024-10-07	Downgrade	Evercore ISI	Outperform → In-line
2024-10-02	Downgrade	BofA Securities	Buy → Neutral
2024-10-01	Downgrade	Citigroup	Neutral → Sell
2024-08-08	Downgrade	JP Morgan	Overweight → Neutral
2024-08-08	Downgrade	Robert W. Baird	Outperform → Neutral
2024-06-28	Downgrade	Argus	Buy → Hold
2024-06-07	Iniziato	Mizuho	Neutral
2024-06-06	Iniziato	Goldman	Buy
2024-02-15	Downgrade	Guggenheim	Buy → Neutral
2023-09-13	Iniziato	TD Cowen	Market Perform
2023-07-10	Downgrade	Citigroup	Buy → Neutral
2023-02-23	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-12	Downgrade	Jefferies	Buy → Hold
2022-09-30	Aggiornamento	Jefferies	Hold → Buy
2022-08-25	Iniziato	Credit Suisse	Outperform
2022-08-04	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Iniziato	Guggenheim	Neutral
2022-04-25	Downgrade	Jefferies	Buy → Hold
2022-04-07	Iniziato	Stephens	Overweight
2022-02-17	Reiterato	BofA Securities	Buy
2022-02-17	Aggiornamento	Citigroup	Neutral → Buy
2022-02-17	Reiterato	Deutsche Bank	Buy
2022-02-17	Reiterato	Morgan Stanley	Overweight
2022-02-17	Reiterato	UBS	Buy
2021-08-05	Ripresa	Credit Suisse	Neutral
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-09-10	Aggiornamento	Jefferies	Hold → Buy
2020-07-01	Aggiornamento	BofA Securities	Neutral → Buy
2020-05-13	Aggiornamento	UBS	Neutral → Buy
2020-04-21	Downgrade	Jefferies	Buy → Hold
2020-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Iniziato	Deutsche Bank	Buy
2020-02-18	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2020-01-10	Aggiornamento	Goldman	Neutral → Buy
2020-01-08	Iniziato	Wells Fargo	Overweight
2020-01-07	Iniziato	Citigroup	Buy
2019-10-18	Downgrade	BofA/Merrill	Buy → Neutral
2019-06-10	Iniziato	SVB Leerink	Outperform
2019-04-30	Ripresa	Evercore ISI	Outperform
2018-12-14	Iniziato	Deutsche Bank	Buy
2018-10-09	Iniziato	UBS	Neutral
2018-08-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2018-07-17	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Aggiornamento	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Aggiornamento	SunTrust	Hold → Buy

Mostra tutto

Charles River Laboratories International Inc Borsa (CRL) Ultime notizie

05:53 AM

A Look At Charles River Laboratories (CRL) Valuation After Its Earnings Beat And New US$1b Buyback - simplywall.st

05:53 AM

10:16 AM

Charles River announces strategic review including 'examination of various alternatives' - MSN

10:16 AM

Mar 13, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 13, 2026

Charles River Laboratories Hits Day Low of $151.91 Amid Price Pressure - Markets Mojo

Mar 13, 2026

Are Charles River’s New Advanced Therapy Deals Quietly Rewriting Its Drug-Development Moat Story (CRL)? - simplywall.st

Mar 13, 2026

Mar 12, 2026

Charles River Laboratories (CRL) slides 9.6% as investors refocus on restructuring, mixed 2026 outlook, and overhang risks - Quiver Quantitative

Mar 12, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 12, 2026

Charles River Labs Stock: Strong Performance vs. Underlying Business ChallengesNews and Statistics - IndexBox

Mar 12, 2026

Zacks Research Has Optimistic Outlook of CRL Q2 Earnings - MarketBeat

Mar 12, 2026

Mackenzie Financial Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat

Mar 12, 2026